Shawn Tomasello biography
Shawn Cline Tomasello serves as Non-Executive Independent Director of the Company. Ms Tomasello has been Chief Commercial Officer at leading immuno-oncology cell therapy company Kite Pharma, where she played a pivotal role in the company’s acquisition in 2017 by Gilead Sciences for $11.9 billion. Prior to this she served as Chief Commercial Officer at Pharmacyclics, Inc., which was acquired in 2015 by AbbVie, Inc. for $21 billion. Ms Tomasello previously was President of the Americas, Hematology and Oncology at Celgene Corporation where she managed over $4 billion in product revenues, and was instrumental in various global expansion and acquisition strategies. She has also held senior positions at Genentech, Pfizer Laboratories, Miles Pharmaceuticals and Procter & Gamble. Ms Tomasello currently serves on the Board of Directors of Centrexion Therapeutics, Corp., Oxford Bio Therapeutics, Ltd., Diplomat Pharmacy, Inc., Gamida Cell, Ltd. and UroGen Pharma, Ltd. She previously served on the Board of Clementia Pharmaceuticals, Inc. which was acquired by Ipsen, SA. as well as Geneos Therapeutics, Inc. She received a MBA from Murray State University and a B.S. in Marketing from the University of Cincinnati. Her extensive experience in the pharmaceutical and biotech industries, particularly in the commercial and transactional fields, provides industry, leadership and management expertise.
What is the salary of Shawn Tomasello?
As the Non-Executive Independent Director of Mesoblast, the total compensation of Shawn Tomasello at Mesoblast is AUD$171,739. There are 8 executives at Mesoblast getting paid more, with Silviu Itescu having the highest compensation of $2,651,590.
